Terrified after my diagnostic mammogram ultrasound — spiculated mass . . . However, recommend ultrasound-guided core needle biopsy in thecontext of left breast findings Left Breast:-3:00, 3 cm from the nipple, corresponding to the mammographic mass: 2 0x 1 0 x 1 7 cm spiculated mass with posterior acoustic shadowing andassociated vascularity A bridge of tissue extends from the mass to thebase of the left nipple
PREDICT: Updated Breast Cancer Survival Calculator Tool The PREDICT "survival calculator", based in the UK, has updated their algorithm as of Spring 2024 to include additional data inputs such as progesterone receptor status, smoker status, metastases status, plus an option for patients who accept or decline radiation
Use of Signatera testing in stable disease I was diagnosed with Stage IV, HR- and HER2+ breast cancer after being in remission for 10 years Since I started treatment last year, I've had 12 infusions overall, 11 infusions have been with Enhertu Perjeta I dose reduced after the first 4 infusions as the DESTINY-Breast09 cancer trial allowed 3 dose reductions of Enhertu
Discontinuing Anastrozole — Community Discussion Forums Refusing Hormonal Therapy for Breast Cancer: What to Know A study published in 2016 found that postmenopausal women who stopped hormonal therapy early were 35% to 56% more likely to have a recurrence than those who didn’t stop taking the medicine early
Signatera test -pros cons — Community Discussion Forums For early-stage breast cancer, the aim of these tests is to detect, and treat, cancer cells before they develop into a full-blown recurrence, thereby improving prognosis
Living with metastatic disease - Community Discussion Forums Has anyone seen this, or have any experience with this? I have MBC right now just breast and bone, (but have previously had cancer in my brain, liver, and leptomeningeal) I'm especially interested in…
PREDICT BREAST CANCER CALCULATOR : NEW VERSION V. 3 Predict Breast Online has released a newer version of their survival calculator This new version is based on women diagnosed between 2000 and 2017, vs 1999 and 2003 for the former version